Article Text

Download PDFPDF

Response to: ‘Achieving lupus low disease activity and remission states under belimumab in refractory systemic lupuserythematosus: time and organ involvement matter’ by Sbeih et al
  1. Mandana Nikpour1,2,
  2. Molla Huq1,2,
  3. Shereen Oon1,2
  1. 1Department of Medicine, The University of Melbourne at St Vincent's Hospital, Fitzroy, Victoria, Australia
  2. 2Department of Rheumatology, The University of Melbourne at St Vincent's Hospital, Fitzroy, Victoria, Australia
  1. Correspondence to Dr Mandana Nikpour, Department of Medicine, University of Melbourne, Fitzroy, VIC 3010, Australia; m.nikpour{at}unimelb.edu.au

Statistics from Altmetric.com

We thank Sbeih et al for their interest in our work. In their correspondence, they show longer time taken to achieve the Lupus Low Disease Activity State (LLDAS) and ‘remission’ than the Systemic Lupus Erythematosus Responder Index-4 (SRI-4) endpoint in a case series of 50 patients with SLE and active disease treated with intravenous belimumab 10 mg/kg.1 Sbeih et al state that the analyses we undertook in the study by Oon et al,2 which was a post hoc evaluation of BLISS-52 and BLISS-76 trials for the LLDAS endpoint, ‘lack data on the time needed to achieve LLDAS…’. However, this is not correct. In supplementary figure 1A) of the publication by Oon et al …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles